Liang, Yong

CAR-NK cells: A promising cellular immunotherapy for cancer

Xie, G., Dong, H., Liang, Y., Ham, J. D., Rizwan, R., & Chen, J. (2020) · eBioMedicine

CAR-T cell therapy researchImmune Cell Function and Interaction

Cited by 800

PD‐L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade

Peng, Q., Qiu, X., Zhang, Z., Zhang, S., Zhang, Y., Liang, Y., Guo, J., Peng, H., Chen, M., Fu, Y.-X., et al. (2020) · Nature Communications

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 553

DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity

Lu, C., Guan, J., Lu, S., Jin, Q., Rousseau, B., Lu, T., Stephens, D., Zhang, H., Zhu, J., Yang, M., et al. (2021) · Cancer Cell

Cancer Immunotherapy and Biomarkersinterferon and immune responses

Cited by 285

A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control

Sun, Z., Ren, Z., Yang, K., Liu, Z., Cao, S., Deng, S., Xu, L., Liang, Y., Guo, J., Bian, Y., et al. (2019) · Nature Communications

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 211

Innate Lymphoid Cells Control Early Colonization Resistance against Intestinal Pathogens through ID2-Dependent Regulation of the Microbiota

Guo, X., Liang, Y., Zhang, Y., Lasorella, A., Kee, B. L., & Fu, Y.-X. (2015) · Immunity

IL-33, ST2, and ILC PathwaysGut microbiota and health

Cited by 138

Type I IFN activating type I dendritic cells for antitumor immunity

Liang, Y., Hannan, R., & Fu, Y.-X. (2021) · Clinical Cancer Research

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 91